CKI has been approved by the State Food and Drug Administration (SFDA) of China for clinical use since 1995 [2] (State medical license no. Z14021231) and it has been clinically used to treat a variety of cancers including lung cancer, liver cancer, breast cancer, ovarian cancer and colorectal cancer [10]. Here, CHKA is linked to liver cancer.